These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8962349)

  • 1. Prevention of the OKT3 first-dose syndrome by reduced initial dose followed by adjusted doses based on CD3 T-lymphocyte counts in pediatric renal graft recipients.
    Piatosa B; Grenda R; Prokurat S
    Transplant Proc; 1996 Dec; 28(6):3466-7. PubMed ID: 8962349
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of adjusted-dose vs standard-dose OKT3 therapy of acute rejection in pediatric kidney transplant recipients.
    Piatosa B; Grenda R; Prokurat S
    Transplant Proc; 1993 Aug; 25(4):2574. PubMed ID: 8356675
    [No Abstract]   [Full Text] [Related]  

  • 3. FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis.
    Kliem V; Eberhard OK; Oldhafer K; Schlitt HJ; Behrend M; Schaumann D; Pichlmayr R; Koch KM; Brunkhorst R
    Transplant Proc; 1996 Dec; 28(6):3166-8. PubMed ID: 8962227
    [No Abstract]   [Full Text] [Related]  

  • 4. Pentoxifylline reduces the first-dose reactions following OKT3.
    Vincenti FG; Vasconcelos M; Birnbaum JL; Tomlanovich SJ; Amend WJ; Melzer JS; Snyder JP
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):57-9. PubMed ID: 8465428
    [No Abstract]   [Full Text] [Related]  

  • 5. OKT3 prophylaxis in kidney transplant recipients: drug monitoring by flow cytometry.
    Cinti P; Cocciolo P; Evangelista B; Orlandini AM; Bruzzone P; Renna Molajoni E; Cortesini R
    Transplant Proc; 1996 Dec; 28(6):3214-6. PubMed ID: 8962245
    [No Abstract]   [Full Text] [Related]  

  • 6. [Muromonab CD3].
    Akioka Y; Hattori M; Ito K
    Nihon Rinsho; 2005 May; 63 Suppl 5():747-50. PubMed ID: 15954439
    [No Abstract]   [Full Text] [Related]  

  • 7. In situ antigenic modulation of human graft-infiltrating T cells is induced by OKT3 treatment.
    Caillat-Zucman S; Legendre C; Noel LH; Bach JF; Kreis H; Chatenoud L
    Transplant Proc; 1990 Aug; 22(4):1782. PubMed ID: 2143860
    [No Abstract]   [Full Text] [Related]  

  • 8. Low-dose OKT3 for cadaveric renal transplantation.
    Schweizer RT; Roper L; Hull D; Bartus SA
    Transplant Proc; 1992 Dec; 24(6):2592-3. PubMed ID: 1465875
    [No Abstract]   [Full Text] [Related]  

  • 9. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
    Norman DJ; Barry JM; Bennett WM; Munson JL; Meyer M; Henell K; Kimball J; Hubert B
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
    [No Abstract]   [Full Text] [Related]  

  • 10. Measures to improve early results in kidney transplantation.
    Schweizer RT; Roper L; Hull D; Bartus S
    Transplant Proc; 1992 Dec; 24(6):2729-30. PubMed ID: 1465919
    [No Abstract]   [Full Text] [Related]  

  • 11. Consequences of OKT3 administration via continuous infusion as compared to bolus infusion.
    ten Berge RJ; Buysmann S; van Diepen FN; Surachno S; Hack CE
    Transplant Proc; 1996 Dec; 28(6):3217-20. PubMed ID: 8962246
    [No Abstract]   [Full Text] [Related]  

  • 12. OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity.
    Vasquez EM; Fabrega AJ; Pollak R
    Transplant Proc; 1995 Feb; 27(1):873-4. PubMed ID: 7879215
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytokine-release syndrome: differences between high and low doses of OKT3.
    Norman DJ; Kimball JA; Barry JM
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420
    [No Abstract]   [Full Text] [Related]  

  • 14. Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation.
    Broughan TA; Valenzuela R; Escorcia E; Secic M; Vogt DP
    Clin Transplant; 1994 Oct; 8(5):488-91. PubMed ID: 7819617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus infection during OKT3 treatment for renal allograft rejection.
    Morgan JD; Horsburgh T; Simpson A; Donnelly PK; Veitch PS; Bell PR
    Transplant Proc; 1992 Dec; 24(6):2634-5. PubMed ID: 1334589
    [No Abstract]   [Full Text] [Related]  

  • 16. Two low-dose OKT3 induction regimens following renal transplantation--clinical experience at a single center.
    Oh HK; Provenzano R; Tayeb J; Satmary N; Jones B
    Clin Transplant; 1998 Aug; 12(4):343-7. PubMed ID: 9686329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single dose OKT3: adverse effects, pharmacokinetics, and anti-OKT3 antibody response.
    Madden RL; Schroeder TJ; Alexander JW; First MR
    Transplant Sci; 1994 Sep; 4(1):111-4. PubMed ID: 7804689
    [No Abstract]   [Full Text] [Related]  

  • 18. Visual loss complicating OKT3 monoclonal antibody therapy in a renal transplant recipient.
    Jin DC; Kim SY; Lee JM; Koo WS; Choi EJ; Yoon YS; Bang BK
    Nephrol Dial Transplant; 1995 Nov; 10(11):2144-6. PubMed ID: 8643188
    [No Abstract]   [Full Text] [Related]  

  • 19. Pentamidine inhalation as a prophylaxis against Pneumocystis carinii pneumonia after therapy of acute renal allograft rejection with orthoclone (OKT3).
    Spieker C; Barenbrock M; Tepel M; Buchholz B; Rahn KH; Zidek W
    Transplant Proc; 1992 Dec; 24(6):2602-3. PubMed ID: 1465879
    [No Abstract]   [Full Text] [Related]  

  • 20. Low-dose OKT3 induction therapy following renal transplantation leads to improved graft function and decreased adverse effects.
    Brown M; Korb S; Light JA; Light T; Jonsson J; Aquino A
    Transplant Proc; 1993 Feb; 25(1 Pt 1):553-5. PubMed ID: 8438411
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.